Literature DB >> 1418695

Acute ketotifen overdosage. A review of present clinical experience.

I Le Blaye1, B Donatini, M Hall, P Krupp.   

Abstract

Ketotifen (Zaditen) is a widely used prophylactic antiasthmatic drug with pronounced antianaphylactic properties and a specific H1-antihistaminic effect. This article summarises the available information on acute overdosage of this drug, which was reported in 13 adults and 8 children. The symptoms of acute overdosage observed with ketotifen are similar to those described for antihistaminic agents. However, it would appear that the acute toxicity of ketotifen is rather low, since no serious effects have been reported either in children or in adults after the intake of up to 20mg of ketotifen, which is 10 times the recommended dose. No lethal outcome of acute overdosage has been described in association with this drug. Ketotifen seems to be better tolerated in children than in adults. Based on present clinical experience, management of acute overdosage includes gastric lavage within 2 to 4h after ingestion or activated charcoal after this period. Symptomatic treatment is indicated if arrhythmias, hypotension or seizures develop, and the patient should be kept under surveillance for at least 6 to 8h.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1418695     DOI: 10.2165/00002018-199207050-00007

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  5 in total

Review 1.  A new approach to the treatment of asthma.

Authors:  P J Barnes
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

2.  Ketotifen overdose: surveillance of the toxicity of a new drug.

Authors:  D B Jeffreys; G N Volans
Journal:  Br Med J (Clin Res Ed)       Date:  1981-05-30

Review 3.  Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders.

Authors:  S M Grant; K L Goa; A Fitton; E M Sorkin
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

4.  Effect of azelastine and ketotifen on the bronchial and skin responses to platelet-activating factor in humans.

Authors:  C K Lai; S Ollier; C K Lau; S T Holgate
Journal:  Clin Exp Allergy       Date:  1991-07       Impact factor: 5.018

Review 5.  Oral activated charcoal in the treatment of intoxications. Role of single and repeated doses.

Authors:  P J Neuvonen; K T Olkkola
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Jan-Dec
  5 in total
  3 in total

1.  Ketotifen controlled release from cellulose acetate propionate and cellulose acetate butyrate membranes.

Authors:  Manuela C C M Sobral; Abilio J F N Sobral; J T Guthrie; M H Gil
Journal:  J Mater Sci Mater Med       Date:  2007-07-10       Impact factor: 3.896

Review 2.  H1-receptor antagonists. Comparative tolerability and safety.

Authors:  F E Simons
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

Review 3.  Safety and tolerability of treatments for allergic rhinitis in children.

Authors:  Carlos E Baena-Cagnani
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.